– EMERALD Study will investigate the safety and efficacy of RTX001, an engineered macrophage cell therapy, in patients with end-stage liver disease – Recruitment already underway in the U.K., following recent MHRA approval EDINBURGH, Scotland and LONDON, Nov. 19, 2024 /PRNewswire/ –…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.